Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

101. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. (Abstract)

Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation, and has many components including mucus hypersecretion, oxidative stress, and airway inflammation. We aimed to assess whether carbocisteine, a mucolytic agent with anti-inflammatory and antioxidation activities, could reduce the yearly exacerbation rate in patients (...) with COPD.We did a randomised, double-blind, placebo-controlled study of 709 patients from 22 centres in China. Participants were eligible if they were diagnosed as having COPD with a postbronchodilator forced expiratory volume in 1 s (FEV(1)) to forced vital capacity (FVC) ratio (FEV(1)/FVC) of less than 0.7 and an FEV(1) between 25% and 79% of the predicted value, were aged between 40 and 80 years, had a history of at least two COPD exacerbations within the previous 2 years, and had remained clinically

2008 Lancet Controlled trial quality: predicted high

102. Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation

, the Netherlands. Patients: 210 patients >40 years of age (mean age 71 y, 75% men) who were admitted to hospital for chronic obstructive pulmonary disease (COPD) exacerbation (history of increased breathlessness and >1 of the following for ⩾24 hours: increased cough frequency or severity, increased sputum volume or purulence, and increased wheeze), had a history of ⩾10 pack-years cigarette smoking, and evidence of airflow limitation (forced expiratory volume in 1 second [FEV 1 ]/forced vital capacity ratio <70 (...) Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation Oral prednisolone was not inferior to intravenous prednisolone for treatment failure in chronic obstructive pulmonary disease exacerbation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use

2008 Evidence-Based Medicine

103. Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD

Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD Article Text Therapeutics Review: corticosteroids plus LABAs reduce exacerbations

2008 Evidence-Based Medicine

104. Review: corticosteroids plus long-acting Beta-agonists reduce exacerbations more than long-acting Beta-agonists alone in COPD

Review: corticosteroids plus long-acting Beta-agonists reduce exacerbations more than long-acting Beta-agonists alone in COPD Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone in COPD | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: corticosteroids plus long-acting β-agonists reduce exacerbations more than long-acting β-agonists alone in COPD Article Text Therapeutics

2008 Evidence-Based Medicine

105. [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation]

publication URL Indexing Status Subject indexing assigned by CRD MeSH Diagnostic Tests, Routines; Patient Admission; Pulmonary Disease, Chronic Obstructive Language Published Spanish Country of organisation Spain English summary An English language summary is available. English Summary English summary available Address for correspondence Unidad de Evaluacion de Tecnologias Sanitarias, Agencia Lain Entralgo/Lain Entralgo Agency, C/ Gran Via 27, 7th floor, ES-28013 Madrid Spain Tel: +34 91 3089480 Fax: +34 (...) [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation] Estandares de uso adecuado de tecnologias sanitarias. Creacion de criterios explicitos de indicacion de ingreso hospitalario en la exacerbacion de EPOC [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation] Estandares de uso adecuado de tecnologias sanitarias. Creacion de

2008 Health Technology Assessment (HTA) Database.

106. COPD exacerbations: defining their cause and prevention. (Abstract)

COPD exacerbations: defining their cause and prevention. Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, leading to substantial morbidity and mortality. COPD exacerbations are associated with increased airway and systemic inflammation and physiological changes, especially the development of hyperinflation. They are triggered mainly by respiratory viruses and bacteria, which infect the lower airway and increase airway inflammation. Some (...) patients are particularly susceptible to exacerbations, and show worse health status and faster disease progression than those who have infrequent exacerbations. Several pharmacological interventions are effective for the reduction of exacerbation frequency and severity in COPD such as inhaled steroids, long-acting bronchodilators, and their combinations. Non-pharmacological therapies such as pulmonary rehabilitation, self-management, and home ventilatory support are becoming increasingly important

2007 Lancet

107. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review

Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

108. Review: tiotropium reduces exacerbations and hospital admissions in COPD and improves quality of life Full Text available with Trip Pro

admissions in COPD and improves quality of life Free Matthew B Stanbrook , MD, PhD Statistics from Altmetric.com Barr RG, Bourbeau J, Camargo CA, et al. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005 ;(2):CD002876. Q In patients with stable chronic obstructive pulmonary disease (COPD), is tiotropium more effective than placebo or other bronchodilators for reducing the risk of clinical end points? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM (...) pulmonary disease, tiotropium reduces exacerbations and hospital admissions, and improves health related quality of life. Abstract and commentary also appear in ACP Journal Club. Commentary The well executed meta-analysis by Barr et al documents compelling evidence for the efficacy of tiotropium in COPD. Tiotropium has shown beneficial effects for most outcomes that clinicians and patients with COPD consider important. Notable exceptions include mortality and decline in lung function over time. However

2006 Evidence-Based Medicine

109. Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease. (Abstract)

Oxygen therapy in the pre-hospital setting for acute exacerbations of chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality in the developed world, is characterised by acute deterioration in symptoms. During these exacerbations, people are prone to developing alveolar hypoventilation, which may be contributed to by the administration of high inspired oxygen concentrations.The objective of the review was to determine (...) the effect of different inspired oxygen concentrations ("high flow" compared to "controlled") in the pre-hospital setting on outcome for people with acute exacerbations of COPD.We searched the Cochrane Airways Group Specialised Register (August 2005), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2005), MEDLINE (1966 to August 2005), EMBASE (1980 to wk 32, 2005), CINAHL (1982 to August wk 1, 2005) and reference lists of articles. We also contacted authors of identified

2006 Cochrane

110. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. (Abstract)

Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Acute exacerbation of chronic obstructive pulmonary disease (COPD) is 1 of the 10 leading causes of hospitalization among adults in the United States.To evaluate the quality of care provided to patients hospitalized for acute exacerbations of COPD and to determine whether hospital or patient characteristics influence treatment.Retrospective cohort study.360 hospitals throughout the United (...) of these nonrecommended care elements, and 22,929 (33%) received ideal care, defined as all of the recommended care processes and none of the nonrecommended ones. Individual hospital performance varied widely; whereas older patients and women were more likely to receive ideal care than their counterparts, a higher annual volume of admissions for COPD was not associated with improved hospital performance.The study used administrative data, not chart review, and was limited to the inpatient management of COPD.The

2006 Annals of Internal Medicine

111. Patients with acute exacerbations of COPD saw anxiety as a sign, rather than cause, of breathlessness Full Text available with Trip Pro

as a sign, rather than cause, of breathlessness Free Paula M Meek , PhD , RN, FAAN Statistics from Altmetric.com Bailey PH. The dyspnea-anxiety-dyspnea cycle—COPD patients’ stories of breathlessness: “It’s scary /when you can’t breathe. ” Qual Health Res 2004 ; 14 : 760 –78. Q How do patients describe the relation between anxiety and the experience of dyspnoea (ie, perception of shortness of breath) during an acute exacerbation of chronic obstructive pulmonary disease (COPD)? DESIGN Focused ethnography (...) hospital stay. Questions were based on the chronic illness model of Strauss et al , which defined acute COPD exacerbation as a medical crisis of a chronic illness. Narrative analysis was used to analyse 3 genres of the 503 stories identified from transcribed interviews: first-person event-specific stories recreating a discrete moment in time; generic or habitual stories of the general course of events over time; and kernel stories suggesting untold first-person event-specific personal stories. MAIN

2006 Evidence-Based Nursing

112. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. (Abstract)

Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Diagnosis of pulmonary embolism (PE) is difficult in patients with chronic obstructive pulmonary disease (COPD) and exacerbation.To evaluate PE in patients with COPD and exacerbation of unknown origin and explore factors associated with PE.Prospective cohort study.University-affiliated hospital in France.211 consecutive patients, all current or former smokers (...) with COPD, who were admitted to the hospital for severe exacerbation of unknown origin and did not require invasive mechanical ventilation.Spiral computed tomography angiography (CTA) and ultrasonography within 48 hours of admission and assessment of the Geneva score. Patients were classified as PE positive (positive results on CTA or negative results on CTA and positive results on ultrasonography) or PE negative (negative results on CTA and negative results on ultrasonography or negative results on CTA

2006 Annals of Internal Medicine

113. Review: hospital at home is as effective as inpatient care for mortality and hospital readmissions in patients with acute exacerbations of chronic obstructive pulmonary disease Full Text available with Trip Pro

obstructive pulmonary disease: systematic review of evidence. BMJ 2004 ; 329 : 315 . Q Is hospital at home (HaH) as effective as inpatient care for reducing mortality and readmission to hospital in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD)? METHODS Data sources: Medline, EMBASE/Excerpta Medica, Science Citation Index, Cochrane Controlled Trials register, UK National Research Register, Web of Science, individual respiratory journal websites, and proceedings (...) Review: hospital at home is as effective as inpatient care for mortality and hospital readmissions in patients with acute exacerbations of chronic obstructive pulmonary disease Review: hospital at home is as effective as inpatient care for mortality and hospital readmissions in patients with acute exacerbations of chronic obstructive pulmonary disease | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie

2006 Evidence-Based Mental Health

114. N-Acetylcysteine and exacerbations of chronic obstructive pulmonary disease

limitations to this review but, overall, the authors’ cautions conclusions appear appropriate. Authors' objectives To evaluate the effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease (COPD). Searching MEDLINE, CINAHL, International Pharmaceutical Abstracts and the Cochrane CENTRAL Register were searched from inception to November 2005 using the reported search terms. In addition, the reference lists in identified studies were screened and experts in the field were (...) reasons for significant heterogeneity were examined. There were limitations to this review but, overall, the authors’ cautious conclusions appear appropriate. Implications of the review for practice and research The authors did not state any implications for practice or further research. Funding NIH, grant numbers K23 HL04385, P01 HL31992 and K08 HL04407. Bibliographic details Sutherland E R, Crapo J D, Bowler R P. N-Acetylcysteine and exacerbations of chronic obstructive pulmonary disease. Journal

2006 DARE.

115. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD

Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

116. Review: long acting B2 agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease Full Text available with Trip Pro

: long acting β 2 agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease Free Sandra Small , RN, MScN Statistics from Altmetric.com Sin DD, McAlister FA, Man SF, et al . Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003 ; 290 : 2301 –12. Q What are the effects of common treatments for chronic obstructive pulmonary disease (COPD) on patient outcomes? METHODS Data sources: Medline (1980 to 1 May 2002), Cochrane (...) pulmonary disease* CONCLUSION Long acting (LA) β 2 agonists (β 2 As) and inhaled corticosteroids, with and without LAβ 2 As, reduce exacerbations but not mortality in patients with chronic obstructive pulmonary disease A modified version of this abstract appears in ACP Journal Club and Evidence-Based Medicine. Commentary The review by Sin et al contributes to the knowledge base on pharmacological and non-pharmacological management of COPD by going beyond evaluation of physiological endpoints

2005 Evidence-Based Nursing

117. Review: methylxanthines are not effective for acute exacerbations of chronic obstructive pulmonary disease Full Text available with Trip Pro

exacerbations of chronic obstructive pulmonary disease, methylxanthines do not improve lung function after 2 hours, clinical outcomes, or symptoms and increase nausea or vomiting. Abstract and commentary also appear in ACP Journal Club. Commentary It was not so long ago that most experts recommended theophylline as a first line agent for treating both stable and exacerbated COPD. Theophylline use increased dramatically during the 1970s, but then waned just as quickly during the 1990s. These rapid shifts (...) for acute exacerbations of chronic obstructive pulmonary disease Free Dennis E Niewoehner , MD Statistics from Altmetric.com Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003 ; 327 : 643 –8. Q In patients with acute exacerbations of chronic obstructive pulmonary disease (COPD), what is the effectiveness of the addition of methylxanthines to standard treatments? Clinical impact ratings GP/FP/Primary

2005 Evidence-Based Medicine

118. Review: long acting ß2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease Full Text available with Trip Pro

. CONCLUSION Long acting (LA) β 2 agonists (β 2 As) and inhaled corticosteroids, with and without LAβ 2 As, reduce exacerbations but not mortality in patients with chronic obstructive pulmonary disease. Abstract and commentary also appear in ACP Journal Club and Evidence-Based Nursing. Commentary The review by Sin et al covers a wide range of treatments for COPD. Breadth is achieved at the expense of detail, but the authors provide a useful overview. A major criticism of respiratory medicine has been (...) Therapeutics Review: long acting β 2 -agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease Free P John Rees , MD Statistics from Altmetric.com Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003 ; 290 : 2301 –12. Q What are the effects of common treatments for chronic obstructive pulmonary disease (COPD) on patient outcomes? Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM

2005 Evidence-Based Medicine

119. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Full Text available with Trip Pro

Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Non-invasive positive pressure ventilation (NPPV) is being used increasingly in the management of patients admitted to hospital with acute respiratory failure secondary to an exacerbation of chronic obstructive pulmonary disease (COPD).To determine the efficacy of NPPV in the management of patients with respiratory failure due to an acute exacerbation (...) of COPD.An initial search was performed using the Cochrane Airways Group trials register and other relevant electronic databases. An updated search was conducted in September 2003.Randomised controlled trials comparing NPPV plus usual medical care (UMC) versus UMC alone were selected. Trials needed to recruit adult patients admitted to hospital with respiratory failure due to an exacerbation of COPD and with PaCO(2) > 6 kPa (45 mmHg).Two reviewers independently selected articles for inclusion, evaluated

2004 Cochrane

120. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. Full Text available with Trip Pro

Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. To evaluate the effects of an early community based pulmonary rehabilitation programme after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease (COPD).A single centre, randomised controlled trial.An inner city, secondary and tertiary care hospital in London.42 patients admitted with an acute exacerbation of COPD.An (...) eight week, pulmonary rehabilitation programme for outpatients, started within 10 days of hospital discharge, or usual care.Incremental shuttle walk distance, disease specific health status (St George's respiratory questionnaire, SGRQ; chronic respiratory questionnaire, CRQ) and generic health status (medical outcomes short form 36 questionnaire, SF-36) at three months after hospital discharge.Early pulmonary rehabilitation, compared with usual care, led to significant improvements in median

2004 BMJ Controlled trial quality: predicted high